A phase 1 dose-escalation study of XmAb<sup>®</sup>2513 in patients with relapsed or refractory Hodgkin lymphoma Letter uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Hodgkin Disease

publication date

  • January 2015

Research

keywords

  • Letter

Identity

Digital Object Identifier (DOI)

  • 10.1111/bjh.13152

PubMed ID

  • 25271537

Additional Document Info

start page

  • 902

end page

  • 4

volume

  • 168

number

  • 6